New fabrics prevent the transmission and spread of SARS-CoV-2

Brazilian textile companies have begun producing and marketing fabrics treated with silver and silica nanoparticles developed by the research groups at the Centre for Functional Materials (CDMF) and the Theoretical and Computational Chemistry Laboratory (QTC) at the Universitat Jaume I, in collaboration with the company Nanox Tecnologia, which provide the new fabrics with antibacterial, antifungal and antiviral properties with 99.99% effectiveness.

The research team has published in the international platform of pre-prints bioRiXv the article "Ag nanoparticles-based antimicrobial polycotton fabrics to prevent the transmission and spread of SARS-CoV-2" in which they demonstrate that the use of an aqueous solution of silver nanoparticles mixed with an acrylic-based binder in poly-cotton fabrics is effective as an antimicrobial and has high durability in relation to washing cycles.

Tests carried out have shown that the fabric is effective in inhibiting the SARS-CoV-2 virus, and the pathogens Staphylococcus Aureus, Escherichia Coli and Candida Albicans. Another of the differential characteristics of these fabrics is the prevention of cross infections caused by pathogens, such as bacteria and opportunistic fungi, responsible for the worsening of COVID-19 and other types of virus.

Journal reference:

Tremiliosi, G. C., et al. (2020) Ag nanoparticles-based antimicrobial polycotton fabrics to prevent the transmission and spread of SARS-CoV-2. bioRiXv.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study reveals early immune responses to SARS-CoV-2, offering insights for future COVID-19 treatments